Drug profile · INN
lopinavir
KALETRA
lopinavir (KALETRA) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — lopinavir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
lopinavir (KALETRA) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 protease inhibitor
Primary target: Human immunodeficiency virus type 1 protease
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lopinavir?
lopinavir (KALETRA) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lopinavir?
KALETRA is a marketed brand name for lopinavir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lopinavir?
lopinavir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.